Market Overview

Global Infectious Disease Diagnostics Market size was valued at USD 23.62 Billion in 2023 and is poised to grow from USD 25.80 Billion in 2024 to USD 52.20 Billion by 2032, growing at a CAGR of 9.2 % in the forecast period (2024-2032).

The global infectious disease diagnostics market is a fast-evolving market that is propelled by the growing cases of infectious diseases globally and the growing demand for rapid and accurate diagnostic products. Infectious diseases, which are caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites, not only challenge the health of individuals in society but also have far-reaching effects on the healthcare systems of the world. Detection and diagnosis form the core of good management, containment, and treatment. While science and technology have evolved, so has the science of the diagnosis of infectious diseases also moved in the direction of adopting newer technologies with better sensitivity, specificity, and turnaround time.

One of the principal drivers of the market is the rising rate of re-emerging and emerging infectious diseases, including COVID-19, Ebola, Zika virus, and antimicrobial resistance infections. The resulting pandemics serve as an indicator of the need for strong diagnostic frameworks in safeguarding the prevention of outbreaks and public good. Additionally, enhanced awareness by patients and medical practitioners on the importance of early disease detection has triggered more utilization of cutting-edge diagnostic technologies, from conventional culture through molecular diagnosis to point-of-care testing technologies.

Technical advancements propel the evolution of the marketplace. Molecular diagnostic technology, for example, is in the shape of polymerase chain reaction (PCR), next-generation sequencing (NGS), and isothermal amplification technologies. These molecular technologies have made it possible to detect microorganisms at a genetic level on the fast lane as well as with high accuracy. Convenience and fast-results technologies point of care are gaining popularity even among resource-constrained countries. These advancements are supplemented further with artificial intelligence (AI)-enabled and digital health solution platforms to enhance data interpretation and accuracy in diagnosis.

The increased emphasis on preventive healthcare and regular screening has also fuelled the need for infectious disease diagnosis. Governments and healthcare organizations have been making substantial investments in diagnostic infrastructure and public health programs to counteract the infectious disease burden. Public-private partnerships for cost-effective, scalable diagnostic technologies are also driving the market growth pathway.

But the market is confronted with barriers like demanding regulatory pressures, high prices of advanced diagnostic technologies, and the unavailability of access to proper diagnostic facilities in low-income countries. This notwithstanding, the infectious disease diagnostics market is set to continue growing as it is driven by continuous research and development efforts, rising healthcare spending, and a strong pipeline of new, innovative diagnostic products.

Market Drivers

Increasing Focus on Early Detection and Preventive Healthcare

• The increased focus on preventive medicine and early diagnosis has now become synonymous with a crucial driver in the global infectious disease diagnostics market. Early detection plays an important role in identifying infection in the early stages, making it possible for intervention in timely manner and minimizing the likelihood of complications occurring. Preventive care is based on gaining control over one's health by adopting active methods of coping with diseases through regular diagnostic screening and testing in a way that brings about detection before the appearance of symptoms. This follows due to growing awareness among patients and clinicians of the benefit of early detection in terms of increased treatment success, reduced healthcare cost, and improved quality of life.
• Governments and healthcare agencies worldwide are prioritizing initiatives for promoting preventive medicine. Public health campaigns, subsidized diagnostic programs, and integration of advanced diagnostic technology into routine check-ups fall under this. Early detection becomes particularly important to control highly infectious diseases, as it aids in curtailing their spread and preventing outbreaks.
• Advantages of technology, including molecular diagnostics and point-of-care testing, complement this trend by providing precise and rapid solutions that are accessible. With an ever-growing emphasis among healthcare systems on the importance of prevention over cure, demand for novel diagnostic tools continues to expand, creating a healthy growth trend in the infectious disease diagnostics market.

Key Findings:

• Thermo Fisher Scientific Inc. (US) released the Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit with the CE-IVD marking in January 2023.
• The HCV antibody and antigen status can be simultaneously and independently established from one human plasma or serum sample using Roche's Elecsys HCV Duo immunoassay, introduced in July 2022.
• Siemens Healthineers made available the CLINITEST Rapid COVID-19 + Influenza Test, a PCR test, and the CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay in September 2022.

Growing Investments in Healthcare Infrastructure and Diagnostic Tools

• Higher investments in healthcare infrastructure and diagnostic technology are driving the growth of the global infectious disease diagnostics market significantly. Governments, private sectors, and healthcare systems across the world are investing a significant amount of funds in the development of diagnostic capacity to meet the growing infectious disease burden. The investments are targeted at enhancing laboratory infrastructure, enhancing the supply of cutting-edge diagnostic technologies, and improving the capacity of healthcare systems, particularly in under-served and resource-poor environments.
• This increase in investment has driven the deployment of sophisticated diagnostic tools, such as molecular diagnostics, point-of-care testing analysers, and next-generation sequencers. The advanced diagnostic technologies deliver rapid, accurate, and reproducible identification of infectious diseases, enabling appropriate and timely treatment, as well as better control of disease. Besides, infrastructure investments facilitate the establishment of central labs, mobile diagnosis units, and integrated networks for healthcare delivery, with larger reach and increased patient outcomes.
• Government-launched initiatives and public-private partnerships are the driving forces and factors for scaling innovation as well. Subsidies on diagnostic services or development research of diagnostic technology contributes to the growth in markets. Increasing worldwide healthcare requirements oriented towards the prevention and treatment of diseases translate to higher healthcare infrastructure and diagnostic technology investments that are likely to drive diagnostic efficiency, accessibility, and quality further, thus creating the biggest push for the expansion of the market.

Market Opportunities

Increasing Demand for At-Home and Decentralized Diagnostic Solutions

• The surging need for home-based and decentralized diagnostic products is transforming the market dynamics of the infectious disease diagnostics market. This is facilitated by elevated convenience, accessibility, and speed requirements, especially post recent outbreak of global health crises like the COVID-19 pandemic. Home testing platforms such as self-test kits for as wide a variety of diseases as respiratory disease to sexually transmitted disease enable individuals to track their health at home. Similarly, decentralization of diagnostics brings diagnostics to patients to deliver quick results through man-based health platforms such as clinics, pharmacies, and district health centres.
• Technological advancement has been the primary force behind the affordability, ease of use, and accuracy of these solutions. Technologies such as lateral flow assays, point-of-care molecular diagnosis machines, and smartphone diagnostics present raw results that require little training to interpret. These solutions also clear healthcare systems clogged with work the workload, providing laboratory and hospital enough time to treat more complicated cases.
• The trend aligns with the overall movement towards preventive and personalized medicine because early and low-cost diagnostics are accountable for timely interventions. Additionally, expansion of telemedicine services promotes home diagnostics through remote consultation and treatment. As changing consumer trends take centre stage, the expansion of decentralized diagnostic solutions is likely to rise, leading the way for disease detection and management in the future.

Market Restraining Factors

Shortage of Skilled Healthcare Professionals for Advanced Diagnostics

• Lack of sufficient trained medical staff with the capability to use advanced diagnostic equipment is a major constraint to the growth of the infectious disease diagnostics market. Advanced training and education are essential for using, reading, and maintaining advanced diagnostic equipment such as molecular testing, NGS, and point-of-care automating devices. Most of the healthcare systems, particularly the low- and middle-income economies, do not have sufficient well-trained staff to meet these requirements.
• This deficiency can lead to wasteful use of expensive diagnostic equipment, laboratory error, time lost in disease diagnosis, and poor patient outcomes. Furthermore, technological development occurs at a rate quicker than health care personnel can adapt to, further compounding the problem. Even in the industrialized nations, overloading combined with a lack of continuing education programs prevent health care personnel from being in a position to keep up with new diagnostic technology.
• To solve this challenge, there must be concerted effort towards enhancing training programs, increasing access to education, and developing user-friendly diagnostic tools that reduce dependency on advanced technical knowledge. Investment in telemedicine and AI platform technology is also a solution that can promote ease of this gap by enabling remote consultation and automated processing of data. Solving this challenge is critical to mass effective utilization of advanced diagnostics.

Segmentation Analysis

The market scope is segmented because of by Product & Service, by Type of Testing, by Technology, by Disease Type, by Sample Type, by End User.

• By Product & Service

Based on the Product & Service of the market is segmented into Reagents, Kits, and Consumables, Instruments, Software & Services.

Among the product and service offerings in the infectious disease diagnostics market, the Reagents, Kits, and Consumables segment is the market leader. It enjoys this position owing to several reasons. To start with, reagents, kits, and consumables are an integral component of diagnostic procedures ranging from molecular, serological, and point-of-care tests. Their frequent employment in each and every diagnostic test ensures continuous demand when compared with instruments and software, which remain one-time or occasional expenses.

The increasing prevalence of infectious diseases such as COVID-19, influenza, and sexually transmitted diseases has significantly driven the need for diagnostic reagents and kits. During outbreak periods, demand for reagents and rapid test kits increases exponentially, proving their critical role in disease management. Further, advances in molecular diagnostics, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), have encouraged the application of advanced reagents and consumables dedicated to these technologies.

• By Type of Testing

Based on the Type of Testing of the market is segmented into Laboratory Testing, PoC Testing.

Among the Type of Testing categories of infectious disease tests in the marketplace, Laboratory Testing has always remained the strongest. Laboratory testing comes out on top because it is extremely precise, reliable, and can run a massive number of tests at a time. Laboratory testing utilizes high-level methods like polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and next-generation sequencing (NGS) with the sensitivity and specificity in the detection of causative infectious agents which cannot be replicated. They need to be used to detect complex infections, verify point-of-care (PoC) testing results, and provide in-depth testing, including antimicrobial susceptibility testing.

The facilities and technology in the central labs are contributing even more to the dominance of the segment. There are skilled staff and advanced equipment in hospitals, reference labs, and diagnostic labs for precise diagnosis and complete test capability. Laboratory testing is usually needed for regulation, particularly for looming public health emergencies such as pandemics and epidemics, contributing even more to its position in the market.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America has dominated the infectious disease diagnostics market based on several compelling reasons. The region boasts a highly developed healthcare infrastructure, extensive access to advanced diagnostic technology, and substantial research and development spending. North America is also supported by top-ranked diagnostic companies, established laboratory networks, and strong governmental support for healthcare programs. In addition, the rate of infectious diseases like respiratory infections and sexually transmitted infections is high in the region, thus creating a greater demand for good diagnostics. Awareness of early disease diagnosis and preventive health care is also much greater among the North American people, which Favors greater utilization of high-end diagnostics.

In contrast, the Asia-Pacific infectious disease diagnostic market is expected to develop the fastest. Urbanization is growing very quickly, healthcare spending is on the rise, and awareness regarding infectious diseases is on the rise, which are the major growth drivers in the region. China, India, and Japan are undergoing tremendous growth in healthcare infrastructure and rising demand for diagnostics as they have massive, aging populations and high prevalence of diseases. In addition, the region's growing middle class and increasing investments by global diagnostic companies are driving the growth in the market. The efforts by the government to enhance disease surveillance and enhance access to diagnostics, especially in rural and underserved regions, are in Favor of Asia-Pacific.

List of Companies Profiled

• Hoffmann-La Roche Ltd.
• Abbott
• bioMérieux
• Siemens Healthineers AG
• Danaher
• Thermo Fisher Scientific Inc.
• Hologic, Inc.
• Becton, Dickinson and Company
• Revvity
• Qiagen
• Seegene Inc.
• QuidelOrtho Corporation
• Grifols, S.A.
• DiaSorin S.p.A.
• Bio-Rad Laboratories, Inc.
• Sysmex Corporation
• OraSure Technologies
• Co-Diagnostics, Inc.
• Trinity Biotech
• Genetic Signatures Ltd.
• Epitope Diagnostics, Inc.
• Trivitron Healthcare
• ELITech Group
• Meril Life Sciences Pvt. Ltd.

Key Industry Developments

• The OSOM Flu SARS-CoV-2 Combo Test received an EUA approval in March 2024 from SEKISUI Diagnostics, a global innovator in medical diagnostic development, and is now cleared for use in home and commercial testing environments.
• The FDA, based in the United States, gave Tangen Biosciences and SD Biosensors an Early Use Authorization (EUA) in October of 2023.
• BD will roll out the BD MAX System in the United States in August 2023 upon filing a patent application with the Respiratory Viral Panel.
• EliTech announced the plans to launch ELITE InGenius in 2024 in April 2023. EliVerse is a next-generation, high-throughput molecular diagnostic platform for more than 50 CE-IVD parameters.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Infectious Disease Diagnostics Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Infectious Disease Diagnostics Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Infectious Disease Diagnostics market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Infectious Disease Diagnostics. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Infectious Disease Diagnostics companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Infectious Disease Diagnostics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Infectious Disease Diagnostics Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S.
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 12 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

• To gain insightful analyses of the Infectious Disease Diagnostics market and have comprehensive understanding of the global market and its commercial landscape.
• Assess the production processes, major issues, and solutions to mitigate the development risk.
• To understand the most affecting driving and restraining forces in the market and its impact in the global market.
• Learn about the Infectious Disease Diagnostics market strategies that are being adopted by leading respective organizations.
• To understand the future outlook and prospects for the Infectious Disease Diagnostics market. Besides the standard structure reports, we also provide custom research according to specific requirements.

Research Scope of Infectious Disease Diagnostics Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Infectious Disease Diagnostics Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: